Somatropin

A once-weekly human growth hormone therapy conferred a greater reduction in trunk fat mass and a greater increase in total body lean mass than placebo, according to topline results from a phase 3 trial.

The FDA in June approved a once-weekly human growth hormone analog for children aged 3 years and older with growth hormone deficiency, according to a company press release.

ATLANTA — Adults with growth hormone deficiency have higher health care costs and more comorbidities than those without growth hormone deficiency, according to findings presented at ENDO 2022.

The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, according to an industry press release.